Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort
- 18 December 2023
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 99 (2) , 254-262
Abstract
VEXAS is a prototypic hemato‐inflammatory disease combining rheumatologic and hematologic disorders in a molecularly defined nosological entity. In this nationwide study, we aimed at screenshotting the current diagnostic capabilities and clinical‐genomic features of VEXAS, and tracked UBA1 longitudinal clonal dynamics upon different therapeutics, including allogeneic hematopoietic cell transplant. We leveraged a collaboration between the Italian Society of Experimental Hematology and of Rheumatology and disseminated a national survey to collect clinical and molecular patient information. Overall, 13/29 centers performed UBA1 genomic testing locally, including Sanger sequencing (46%), next‐generation sequencing (23%), droplet digital polymerase chain reaction (8%), or combination (23%). A total of 41 male patients were identified, majority (51%) with threonine substitutions at Met41 hotspot, followed by valine and leucine (27% and 8%). Median age at VEXAS diagnosis was 67 years. All patients displayed anemia (median hemoglobin 9.1 g/dL), with macrocytosis. Bone marrow vacuoles were observed in most cases (89%). The most common rheumatologic association was polychondritis (49%). A concomitant myelodysplastic neoplasm/syndrome (MDS) was diagnosed in 71% of patients (n = 28), chiefly exhibiting lower Revised International Prognostic Scoring System risk profiles. Karyotype was normal in all patients, except three MDS cases showing ‐Y, t(12;16)(q13;q24), and +8. The most frequently mutated gene was DNMT3A (n = 10), followed by TET2 (n = 3). At last follow‐up, five patients died and two patients progressed to acute leukemia. Longitudinal UBA1 clonal dynamics demonstrated mutational clearance following transplant. We collected a nationwide interdisciplinary VEXAS patient cohort, characterized by heterogeneous rheumatologic manifestations and treatments used. MDS was diagnosed in 71% of cases. Patients exhibited various longitudinal UBA1 clonal dynamics.Keywords
Funding Information
- Ministero della Salute (Finalizzata 2018 NET‐2018‐12365935)
- Edward P. Evans Foundation
This publication has 31 references indexed in Scilit:
- Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆Annals of Oncology, 2021
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory DiseaseNew England Journal of Medicine, 2020
- Clonal hematopoiesis in human aging and diseaseScience, 2019
- Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trialsBlood, 2019
- Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromesLeukemia, 2018
- Age-related clonal hematopoiesisBlood, 2018
- CHIP, ICUS, CCUS and other four-letter wordsLeukemia, 2017
- Time-dependent changes in mortality and transformation risk in MDSBlood, 2016
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014
- Epidemiology of Myelodysplastic SyndromesThe American Journal of Medicine, 2012